Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ILLUMINA | 7 | - | -9,07 % | ||
| AMGEN | 6 | 27 | +0,24 % | ||
| BIONTECH | 5 | 13 | -0,06 % | ||
| OCULAR THERAPEUTIX | 5 | 1 | +1,74 % | ||
| ADAPTIVE BIOTECHNOLOGIES | 5 | - | +0,21 % | ||
| ARROWHEAD PHARMACEUTICALS | 4 | - | +0,26 % | ||
| BIOGEN | 3 | 54 | 0,00 % | ||
 | NOVOCURE | 3 | 11 | +0,98 % | |
| ROIVANT SCIENCES | 2 | 3 | +1,00 % | ||
| MBX BIOSCIENCES | 2 | 1 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:42 | Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline | 4 | Seeking Alpha | ||
| 04:53 | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | 582 | wallstreetONLINE | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| 03:42 | Morningstar Expands Index Business With $365 Million CRSP Acquisition | 2 | pulse2.com | ||
| 02:18 | Illumina outlines 2026 revenue guidance of $4.5B-$4.6B while advancing clinical growth and multiomics strategy | 14 | Seeking Alpha | ||
| 00:50 | Torex Gold makes CEO transition: Torex Gold Resources' (TSX:TXG) CEO Jody Kuzenko will be retiring from the company ... | 2 | Mining.com.au | ||
| 00:18 | Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances | 9 | Investing.com | ||
| 00:06 | Adaptive Biotechnologies Q4 2025 slides: 55% revenue growth as MRD business expands | 2 | Investing.com | ||
| Do | Earnings Call Transkript: Illumina übertrifft EPS-Prognose für Q4 2025 um 10,66 % | 2 | Investing.com Deutsch | ||
| Do | Earnings Call: Arrowhead Pharmaceuticals übertrifft Gewinnprognose für Q1 2026, Aktie gibt nach schwachem Ausblick nach | 1 | Investing.com Deutsch | ||
| Do | Earnings Call Transkript: Adaptive Biotechnologies übertrifft Erwartungen für Q4 2025 | 7 | Investing.com Deutsch | ||
| Do | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | 102 | GlobeNewswire (Europe) | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| Do | Illumina-Aktie bricht ein: Stagnierender Umsatz enttäuscht Anleger | 10 | Investing.com Deutsch | ||
| Do | Illumina Inc. Q4 Profit Advances | 259 | AFX News | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) released earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $334 million, or $2.16... ► Artikel lesen | |
| Do | MBX Biosciences sichert sich 87,1 Mio. US-Dollar durch Aktienplatzierung | - | Investing.com Deutsch | ||
| Do | MBX Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Illumina Q4 Earnings Summary & Key Takeaways | 9 | Benzinga.com | ||
| Do | Adaptive Biotechnologies GAAP EPS of -$0.09 beats by $0.09, revenue of $71.7M beats by $10.8M | 6 | Seeking Alpha | ||
| Do | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Adaptive Biotechnologies Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | 72 | GlobeNewswire (Europe) | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.